Today's Research Reports on Biotech Stocks to Watch: Brainstorm Cell Therapeutics and Cyclacel Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / April 7, 2017 / Brainstorm Cell Therapeutics and Cyclacel Pharmaceuticals are hoping continued FDA clinical trials will return positive results as revenues have begun to slow. The companies are working to significantly reduce operating expenses or make significant product breakthroughs.
RDI Initiates Coverage:
Cyclacel Pharmaceuticals Inc. https://ub.rdinvesting.com/news/?ticker=CYCC
Brainstorm Cell Therapeutics Inc. https://ub.rdinvesting.com/news/?ticker=BCLI
Cyclacel Pharmaceuticals slid 7.19% to close at $6.20 on Thursday. The stock traded between $5.72 and $7.25 per share on volume of 2.6 million shares. While there was some positive news announced by the company about its novel PLK1 Inhibitor FDA candidate drug, CYC140, recently released financials have investors cautious. The company reported revenues were $843,000 for the full year 2016, compared to revenues of $1.9 million in 2015.
As for the positive news, President and Chief Executive Officer Spiro Rombotis said, "We believe these [pre-clinical data] findings further validate the potential utility of CYC140 and its selection as a clinical candidate."
Access RDI's Cyclacel Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=CYCC
Brainstorm Cell Therapeutics tumbled 9.78% to close at $4.06 in Thursday's trading session. The stock traded between $3.82 and $4.49 on volume of 993,947 shares traded. The company develops adult stem cell technology for the treatment of neurodegenerative diseases. On March 30th, the company reported end of year annual financials and FDA progress news. The recently successful Phase II testing of NurOwn led to a meeting with the FDA for Phase II testing. A general agreement was reached, and the FDA supported a Biologic License Application for NurOwn.
The company's net loss for the year ending December 31, 2016 was $5.0 million, compared to a net loss of $8.5 million for the same reporting period in 2015. R&D expenses were $2.3 million, compared to $4.9 million a year ago. The drop was primarily due to reduction in FDA clinical trial costs.
Access RDI's Brainstorm Cell Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=BCLI
Our Actionable Research on Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) and Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
